← Pipeline
Registered human trialRecruitingNo efficacy data yet
Phase 2
ACT-1004-1239
CXCR7 / ACKR3 antagonist • progressive MS
Practical availability: Research study — recruiting does not guarantee access
- Compound / intervention
- CXCR7 / ACKR3 antagonist • progressive MS
- Mechanism
- CXCR7 / ACKR3 antagonism
- Development stage
- Phase 2
- Status
- Recruiting
- Population / locations
- Site: Netherlands • the only CTIS country and site
- Evidence level
- Human Phase 2 • results pending
Next substantive checkpoint
MRI, electrophysiological and biochemical remyelination endpoints at 48 weeks
Related substantive developments
No separate substantive update is currently linked.